Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lincomycin Hydrochloride

FDA-approved product (capsule, oral), marketed as Lincocin, Lincomycin Hydrochloride.

Registered studies
50+
Lab records
9
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Lincomycin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection
  • Multiple sclerosis
  • Pseudomembranous enterocolitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Lincosamides
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01FF02

Repurposing investigation

Lincomycin Hydrochloride is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli4.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae8.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis4.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 2 of 3 lab records
  • E. coli: measured active in 0 of 1 lab record
  • K. pneumoniae: measured active in 0 of 1 lab record
  • M. tuberculosis: measured active in 0 of 4 lab records
Open Lincomycin Hydrochloride in ChEMBL Registered studies below
Show the 9 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lincomycin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Clindamycin vs. Benzoyl Peroxide Used in Combination With Clindamycin and Doxycycline in the Treatment of Moderate Acne

    NCT00837213 · start 2007-08

    Registered record
    Registry ID
    NCT00837213
    Conditions
    Acne
    Interventions
    Benzoyl peroxide with clindamycin; Benzoyl peroxide with clindamycin and doxycycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-08
    Completion
    2008-08
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne
    InterventionBenzoyl peroxide with clindamycin; Benzoyl peroxide with clindamycin and doxycycline
    PhasePhase 4
    Registry statusCompleted

  • A Clinical Study Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris

    NCT00664248 · start 2006-10

    Registered record
    Registry ID
    NCT00664248
    Conditions
    Acne Vulgaris
    Interventions
    IDP-110; Clindamycin; Benzoyl peroxide; Vehicle
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-10
    Completion
    Not recorded
    Enrolment
    1,414

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionIDP-110; Clindamycin; Benzoyl peroxide; Vehicle
    PhasePhase 3
    Registry statusCompleted

  • Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections

    NCT00352612 · start 2006-09

    Registered record
    Registry ID
    NCT00352612
    Conditions
    Staphylococcal Infection; Abscess; Staphylococcal Skin Infection; Folliculitis
    Interventions
    clindamycin; cephalexin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-09
    Completion
    2009-08
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcal Infection; Abscess; Staphylococcal Skin Infection; Folliculitis
    Interventionclindamycin; cephalexin
    PhasePhase 4
    Registry statusCompleted

  • Role of Antibiotics to Reduce Infectious Complications in Tube Thoracotomy Management of Traumatic Hemopneumothorax

    NCT01127880 · start 2005-07

    Registered record
    Registry ID
    NCT01127880
    Conditions
    Hemopneumothorax; Pneumothorax
    Interventions
    Ancef or Clindamycin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2005-07
    Completion
    2009-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemopneumothorax; Pneumothorax
    InterventionAncef or Clindamycin; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Prophylaxis of Acute Post-Traumatic Bacterial Endophthalmitis

    NCT00398658 · start 2002-03

    Registered record
    Registry ID
    NCT00398658
    Conditions
    Endophthalmitis; Prophylaxy of Post Traumatic Endophthalmitis; Bacterial Endophthalmitis
    Interventions
    gentamycin and clindamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-03
    Completion
    2004-12
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndophthalmitis; Prophylaxy of Post Traumatic Endophthalmitis; Bacterial Endophthalmitis
    Interventiongentamycin and clindamycin
    PhasePhase 4
    Registry statusCompleted